|
EP1386922B1
(en)
*
|
1996-12-03 |
2012-04-11 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereof, analogues and uses thereof
|
|
US20020058286A1
(en)
*
|
1999-02-24 |
2002-05-16 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
JP4303105B2
(ja)
*
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
二重特異性リガンドとその利用
|
|
US20100234570A1
(en)
*
|
2001-06-28 |
2010-09-16 |
Domantis Limited |
Ligand
|
|
MXPA04011624A
(es)
|
2002-05-24 |
2005-03-07 |
Schering Corp |
Anticuerpo neutralizante humano anti-igfr.
|
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
ATE350383T1
(de)
*
|
2002-08-23 |
2007-01-15 |
Sloan Kettering Inst Cancer |
Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
CA2511910A1
(en)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
ES2372694T3
(es)
*
|
2003-10-15 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
|
|
EP1694850B1
(en)
|
2003-11-12 |
2011-06-29 |
Schering Corporation |
Plasmid system for multigene expression
|
|
US8017321B2
(en)
|
2004-01-23 |
2011-09-13 |
The Regents Of The University Of Colorado, A Body Corporate |
Gefitinib sensitivity-related gene expression and products and methods related thereto
|
|
WO2005082415A2
(en)
*
|
2004-02-25 |
2005-09-09 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
|
|
MXPA06011423A
(es)
|
2004-04-02 |
2007-01-23 |
Osi Pharm Inc |
Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
|
|
JP5422120B2
(ja)
*
|
2004-05-27 |
2014-02-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト |
癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
|
|
JP2008501652A
(ja)
*
|
2004-06-03 |
2008-01-24 |
エフ．ホフマン−ラ ロシュ アーゲー |
ゲムシタビン及びｅｇｆｒインヒビターによる治療
|
|
EP2281841A3
(en)
|
2004-12-03 |
2013-10-23 |
Merck Sharp & Dohme Corp. |
Biomarkers for pre-selection of patients for anti-IGF1R therapy
|
|
US20090163476A1
(en)
*
|
2005-03-03 |
2009-06-25 |
Sirtris Pharmaceuticals, Inc. |
N-Phenyl Benzamide Derivatives as Sirtuin Modulators
|
|
US8383357B2
(en)
*
|
2005-03-16 |
2013-02-26 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
|
|
WO2006101925A2
(en)
*
|
2005-03-16 |
2006-09-28 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
|
|
BRPI0611800A2
(pt)
|
2005-06-15 |
2008-12-09 |
Schering Corp |
formulaÇço estÁvel de anticorpo
|
|
US8093401B2
(en)
*
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US7855289B2
(en)
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US7345178B2
(en)
*
|
2005-08-04 |
2008-03-18 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US8088928B2
(en)
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
|
AU2006292278B2
(en)
*
|
2005-09-20 |
2012-03-08 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
CA2632866A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
|
AU2007235577B2
(en)
|
2006-03-31 |
2011-09-15 |
Janssen Pharmaceutica N.V. |
Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor
|
|
ATE478067T1
(de)
|
2006-03-31 |
2010-09-15 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
|
|
US20080045589A1
(en)
*
|
2006-05-26 |
2008-02-21 |
Susan Kelley |
Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
|
|
WO2008074749A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Nerviano Medical Sciences S.R.L. |
Indazole derivatives as kinase inhibitors for the treatment of cancer
|
|
WO2008079849A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
|
TW200900070A
(en)
*
|
2007-02-27 |
2009-01-01 |
Osi Pharm Inc |
Combination cancer therapy
|
|
US8377636B2
(en)
*
|
2007-04-13 |
2013-02-19 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to kinase inhibitors
|
|
CA2683801A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
|
TW200916472A
(en)
*
|
2007-06-20 |
2009-04-16 |
Sirtris Pharmaceuticals Inc |
Sirtuin modulating compounds
|
|
US8048621B2
(en)
*
|
2007-10-03 |
2011-11-01 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2008307634A1
(en)
*
|
2007-10-03 |
2009-04-09 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2215066A1
(en)
*
|
2007-11-01 |
2010-08-11 |
Sirtris Pharmaceuticals, Inc. |
Amide derivatives as sirtuin modulators
|
|
JP2011503066A
(ja)
*
|
2007-11-08 |
2011-01-27 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
可溶化チアゾロピリジン誘導体
|
|
US8084466B2
(en)
|
2007-12-18 |
2011-12-27 |
Janssen Pharmaceutica Nv |
Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
|
|
ES2402138T3
(es)
|
2007-12-28 |
2013-04-29 |
Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts |
Terapia contra el cáncer con un parvovirus combinado con quimioterapia
|
|
EP2250173A1
(en)
*
|
2008-01-18 |
2010-11-17 |
OSI Pharmaceuticals, Inc. |
Imidazopyrazinol derivatives for the treatment of cancers
|
|
RU2008106419A
(ru)
*
|
2008-02-21 |
2009-08-27 |
Закрытое акционерное общество "Ива фарм" (RU) |
Лекарственные средства на основе олигоядерных координационных соединений d-металлов, способ терапевтического воздействия на организм пациента и способ повышения терапевтической эффективности фармакологически активного вещества
|
|
JP5404606B2
(ja)
|
2008-03-27 |
2014-02-05 |
三菱電機株式会社 |
エレベータの制御システム
|
|
ES2396613T3
(es)
*
|
2008-05-19 |
2013-02-22 |
OSI Pharmaceuticals, LLC |
Imidazopirazinas e imidazotriazinas sustituidas
|
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
|
CN102388054B
(zh)
|
2008-12-19 |
2015-03-04 |
西特里斯药业公司 |
噻唑并吡啶沉默调节蛋白调节剂的化合物
|
|
US20110171124A1
(en)
*
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
|
|
EP2421837A1
(en)
|
2009-04-20 |
2012-02-29 |
OSI Pharmaceuticals, LLC |
Preparation of c-pyrazine-methylamines
|
|
WO2010129740A1
(en)
*
|
2009-05-07 |
2010-11-11 |
Osi Pharmaceuticals, Inc. |
Use of osi-906 for treating adrenocortical carcinoma
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
AU2011223655A1
(en)
*
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
|
WO2012117396A1
(en)
*
|
2011-03-01 |
2012-09-07 |
Novotyr Therapeutics Ltd |
Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
MX2013010898A
(es)
|
2011-03-24 |
2013-12-06 |
Chemilia Ab |
Novedoso derivados de la pirimidina.
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
JO3516B1
(ar)
|
2013-03-06 |
2020-07-05 |
Janssen Pharmaceutica Nv |
مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
|
|
WO2015008206A1
(en)
|
2013-07-14 |
2015-01-22 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
|
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
|
CN107250108B
(zh)
*
|
2015-02-05 |
2020-11-27 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
GB201617627D0
(en)
*
|
2016-10-18 |
2016-11-30 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
CN108473487B
(zh)
*
|
2016-12-13 |
2021-08-03 |
普林斯顿药物研发公司 |
一种蛋白激酶抑制剂
|